Walsall

Researchers are studying the impact and burden of three skin conditions moderate or severe alopecia areata, non-segmental vitiligo, and moderate to severe hidradenitis suppurativa. The study includes adolescents and adults and aims to understand how these conditions affect quality of life and daily functioning in a large global population. This is an observational study where participants with each condition will have a single visit for data collection following routine clinical practice. No experimental treatments are given instead, the study gathers information during this one visit to assess disease characteristics and impact. During the visit, participants will complete questionnaires and clinical assessments specific to their condition. These include tools measuring symptom impact, hair loss severity, skin depigmentation, and quality of life related to each disease. This helps researchers better understand the real-world burden of these conditions. Participation involves only this one visit, with no long-term follow-up or additional procedures.

Researchers are evaluating the safety and effectiveness of ruxolitinib cream in children and adolescents aged 6 to under 18 years with moderate atopic dermatitis. This condition involves skin inflammation and itching, and the study aims to provide new treatment options by comparing ruxolitinib cream to a matching vehicle cream. The trial is a Phase 3b, randomized, double-blind study sponsored by Incyte Corporation. Participants will be assigned randomly to receive either ruxolitinib cream or a vehicle cream. The creams will be applied twice daily or twice weekly depending on the study period. The study includes a vehicle-controlled phase and a disease control phase, with an open-label extension period where all participants may receive ruxolitinib cream. The treatment regimen also allows twice-daily application during disease flare-ups. During the study, participants will regularly visit the clinic for assessments including skin evaluations using the Eczema Area and Severity Index EASI, Investigators Global Assessment, itch severity ratings, and quality of life questionnaires. Blood samples will be taken to measure drug levels and safety labs. The study will monitor adverse events and disease flare-ups for up to 70 weeks. Participants and their guardians will keep diaries to track symptoms and cream usage throughout the trial.

Researchers are evaluating the effectiveness and safety of ruxolitinib cream in children aged 6 to under 12 years who have nonsegmental vitiligo, a condition causing patches of skin to lose pigment. This phase 3 randomized, double-blind study aims to determine how well this topical treatment improves the appearance of vitiligo, especially on the face, while monitoring safety and side effects. Participants are randomly assigned to one of three groups to receive either ruxolitinib cream at 0.75 or 1.5 strength, or a matching placebo cream vehicle. The cream is applied twice daily as a thin film to affected areas defined by the study protocol. The treatment lasts for 24 weeks, during which the response to therapy will be assessed. The study includes a safety follow-up period extending up to 52 weeks to monitor for any treatment-related adverse events. Throughout the study, children will have their vitiligo area scored using facial and total body Vitiligo Area Scoring Index F-VASI and T-VASI at multiple time points. Additional assessments include patient and caregiver impressions of change, quality of life measures, psychosocial impact questionnaires, and pharmacokinetic blood sampling. The main outcome focuses on the proportion of participants achieving at least a 75 improvement in facial vitiligo at 24 weeks. Safety and treatment satisfaction will also be evaluated, with total participation lasting up to one year including follow-up.

Researchers are evaluating the efficacy and safety of tulisokibart in participants with moderately to severely active Crohns disease. This Phase 3 program includes two separate studies with different treatment goals. Study 1 includes both induction and maintenance treatment and aims to see if tulisokibart doses are better than placebo in achieving clinical remission and endoscopic response at 12 and 52 weeks. Study 2 focuses only on induction treatment with similar goals measured at 12 weeks. Participants receive different dosing regimens of tulisokibart administered either intravenously IV or subcutaneously SC. Study 1 has groups receiving high or low dose IV tulisokibart followed by high or low dose SC tulisokibart maintenance, as well as placebo groups matching these routes. Study 2 includes induction treatment with high or low dose IV tulisokibart or placebo. Some participants may continue in extension arms with SC dosing after completing their initial study phase if they meet specific requirements. During the study, participants will be assessed regularly for clinical remission using Crohns Disease Activity Index scores or stool frequency and abdominal pain scores, and for endoscopic response by examination. These assessments occur at weeks 12 and 52 for Study 1 and at week 12 for Study 2. Researchers will monitor safety by tracking adverse events and treatment discontinuations. The total participation duration varies, with Study 1 lasting up to 52 weeks and Study 2 up to 12 weeks.

Researchers are evaluating the Heartfelt device, a new passive monitoring system designed to detect early signs of fluid build-up oedema in patients with heart failure by measuring changes in foot and lower leg volume using 3D images. The study aims to determine if adding this device to standard NHS care improves quality of life and reduces heart failure-related events compared to standard care alone. The trial involves 300 participants across multiple NHS hospitals and GP practices in the UK. Participants will be randomly assigned to one of two groups one receiving standard NHS care, which includes regular weight checks and symptom monitoring, and the other receiving the same care plus the Heartfelt device installed at home. The device captures daily images of the feet to track swelling changes without any extra effort from patients. Alerts are sent to clinical teams if important changes are detected, allowing prompt action. Patients in both groups also receive a British Heart Foundation patient booklet to support understanding and self-monitoring. During the study, participants will have their quality of life assessed at multiple points over 12 months alongside tracking heart failure events, hospitalisations, device data availability, medication use, and mortality. The study will also explore how healthcare teams respond to alerts, usability of the device, and its cost-effectiveness. Patient involvement helps ensure the study findings are relevant and useful for future care. The trial runs for 12 months with ongoing monitoring and data collection.

Researchers are evaluating a new blood test called Avantect to detect pancreatic cancer early in people aged 50 to 84 who were recently diagnosed with type 2 diabetes. Pancreatic cancer is often deadly because it is usually found late. This study aims to see if the Avantect test can find signs of cancer sooner, allowing for earlier treatment and better chances of survival. The study is interventional and includes a large group of participants recruited from general practices over three years. Participants will be randomly assigned to one of two groups the intervention arm or the control arm. Those in the intervention arm will have their blood samples tested with the Avantect test quickly, and if cancer markers are found, they will be informed and offered imaging scans like MRI or CT to check for pancreatic cancer. The control group will have their blood samples stored for possible future testing but will receive standard diabetes care. Blood samples and health outcomes will be tracked for three years. Each participant will attend three study visits over 12 months, providing blood samples and completing anxiety questionnaires. Researchers will monitor cancer diagnosis and mortality through registries for three years after consent. They will evaluate the tests sensitivity, specificity, and ability to detect cancer early enough for surgery. The study also measures predictive values and cancer resectability. This design helps understand the tests potential to improve pancreatic cancer detection in people with new diabetes diagnoses.

Aortic stenosis AS affects many older adults, especially those over 65 years old, with increasing numbers due to an aging population. This condition often progresses silently until serious symptoms appear, requiring valve replacement surgery AVR or transcatheter aortic valve implantation TAVI. This research aims to compare early valve replacement to regular monitoring in patients with severe AS who have no symptoms, to understand which approach leads to better health outcomes and cost-effectiveness. The study is a large, open, randomized controlled trial conducted in multiple countries, including the UK, Australia, and New Zealand. Participants with severe asymptomatic AS will be randomly assigned to receive either early valve replacement surgery or ongoing regular monitoring without immediate surgery. Those in the surgery group will be placed on a waiting list aiming for surgery within three months and may undergo additional routine tests like coronary angiography. The monitoring group will continue with standard care and regular check-ups. Participants will be followed for at least three years to track outcomes such as cardiovascular death and hospitalizations for heart failure, along with quality of life and health economics measurements. The study includes regular assessments, questionnaires, and record linkages up to five years. Researchers will analyze outcomes based on the group participants were assigned to, regardless of actual treatment received, to provide clear information on the benefits and risks of early surgery versus expectant management.

The trial investigates whether stopping or continuing milk feeding around the time of blood transfusion in very premature infants born before 30 weeks gestation affects the risk of developing Necrotizing Enterocolitis NEC, a serious intestinal disease. NEC can cause severe damage or death in preterm infants, and this study aims to find out which feeding approach during transfusion may reduce this risk. The trial is conducted in neonatal intensive care units across Canada and the UK and compares two standard care methods currently in use. Participants are randomly assigned to one of two groups one group will stop all enteral feeds for 4 hours before, during, and 4 hours after packed red cell transfusions, with hydration maintained by intravenous nutrition or glucose the other group will continue feeding as usual throughout the transfusion period. Infants stay in their assigned feeding group until they reach 34 weeks and 6 days gestational age. This approach follows practices identified as acceptable in prior surveys and studies. During the study, infants will be closely monitored for the development of NEC and other health outcomes from randomization until 40 weeks postmenstrual age. Researchers will track serious complications like severe NEC, infections, growth, lung disease, eye problems, brain injury, and hospital stay duration. The study collects detailed information about feeding, infections, nutrition, and clinical status to evaluate the safety and effects of each feeding strategy during transfusion.